Bieżący numer
Archiwum
Online first
O czasopiśmie
Redakcja
Rada Naukowa
Wydawca
Standardy etyczne i procedury
Bazy indeksacyjne
Recenzenci
Recenzenci Honorowi
Prenumerata
Kontakt
Najczęściej czytane artykuły
Dla autorów
Opłata za przetwarzanie artykułu (APC)
Książki i Konferencje
Książki
Konferencje
SARS CoV-2/COVID-19
PRZEGLĄD LITERATURY NA PODSTAWIE PRZYPADKÓW
Different faces of anti-melanoma differentiation-associated gene 5 antibody-positive myositis
1
Department of Rheumatology, Medical University of Lodz, Poland
2
Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Poland
3
Laboratory of Autoinflammatory, Genetic and Rare Skin Disorders, Medical University of Lodz, Poland
Data nadesłania: 11-10-2024
Data ostatniej rewizji: 19-01-2025
Data akceptacji: 08-02-2025
Data publikacji online: 05-12-2025
Autor do korespondencji
Aleksandra Opinc-Rosiak
Department of Rheumatology, Medical University of Lodz, 113 Żeromskiego St., 90-549 Lodz, Poland
Department of Rheumatology, Medical University of Lodz, 113 Żeromskiego St., 90-549 Lodz, Poland
Reumatologia 2025;63(6):435-445
SŁOWA KLUCZOWE
DZIEDZINY
STRESZCZENIE
Dermatomyositis with anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibodies is a rare, poorly recognised and potentially life-threatening subtype of idiopathic inflammatory myopathies. Frequent amyopathic course, unique cutaneous lesions, symptoms interfering with other connective tissue diseases, and low awareness of the disease lead to a delay in establishing the proper diagnosis. Clinical presentations may differ among individuals, and three main patterns have been identified depending on the predominant symptoms and prognosis. Interstitial lung disease and vasculopathy contribute mostly to an unfavourable outcome. The study aimed to present different courses of anti-MDA5 myopathy and highlight the heterogenicity of the disease, based on real-life cases from one centre. This is also the first study to document renal involvement in the form of focal segmental glomerulosclerosis in patient with anti-MDA5 dermatomyositis. The review section broadly describes up-to-date knowledge on the subtypes of anti-MDA5 myopathy, thoroughly exploring its pathogenesis, clinical presentations and currently recommended standards of care.
REFERENCJE (46)
1.
Bohan A, Peter JB. Polymyositis and Dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344–347, DOI: 10.1056/NEJM197502132920706.
2.
Wolstencroft PW, Fiorentino DF. Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies. Curr Rheumatol Rep 2018; 20: 28, DOI: 10.1007/s11926-018-0733-5.
3.
Ghirardello A, Borella E, Beggio M, et al. Myositis autoantibodies and clinical phenotypes. Autoimmun Highlights 2014; 5: 69–75, DOI: 10.1007/s13317-014-0060-4.
4.
Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571–1576, DOI: 10.1002/art.21023.
5.
Betteridge Z, Tansley S, Shaddick G, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 2019; 101: 48–55, DOI: 10.1016/j.jaut.2019.04.001.
6.
Nombel A, Fabien N, Coutant F. Dermatomyositis With Anti- MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies. Front Immunol 2021; 12: 773352, DOI: 10.3389/fimmu.2021.773352.
7.
Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441: 101–105, DOI: 10.1038/nature04734.
8.
Feng Q, Hato SV, Langereis MA, et al. MDA5 Detects the Double- Stranded RNA Replicative Form in Picornavirus-Infected Cells. Cell Rep 2012; 2: 1187–1196, DOI: 10.1016/j.celrep.2012.10.005.
9.
Fuzzi E, Gatto M, Zen M, et al. Anti-MDA5 dermatomyositis: an update from bench to bedside. Curr Opin Rheumatol 2022; 34: 365–373, DOI: 10.1097/BOR.0000000000000908.
10.
Toquet S, Granger B, Uzunhan Y, et al. The seasonality of Dermatomyositis associated with anti-MDA5 antibody: An argument for a respiratory viral trigger. Autoimmun Rev 2021; 20: 102788, DOI: 10.1016/j.autrev.2021.102788.
11.
Nishina N, Sato S, Masui K, et al. Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. RMD Open 2020; 6: e001202, DOI: 10.1136/rmdopen-2020-001202.
12.
Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int 2021; 41: 1021–1036, DOI: 10.1007/s00296-021-04819-1.
13.
De Lorenzis E, Natalello G, Gigante L, et al. What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19? Autoimmun Rev 2020; 19: 102666, DOI: 10.1016/j.autrev.2020. 102666.
14.
Anderle K, Machold K, Kiener HP, et al. COVID-19 as a putative trigger of anti-MDA5-associated dermatomyositis with acute respiratory distress syndrome (ARDS) requiring lung transplantation, a case report. BMC Rheumatol 2022; 6: 42, DOI: 10.1186/s41927-022-00271-1.
15.
Keshtkarjahromi M, Chhetri S, Balagani A, et al. Macrophage activation syndrome in MDA5 antibody-positive dermatomyositis and COVID-19 infection. BMC Rheumatol 2021; 5: 59, DOI: 10.1186/s41927-021-00225-z.
16.
Allenbach Y, Leroux G, Suárez-Calvet X, et al. Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies common interferon signature but distinct NOS2 expression. Am J Pathol 2016; 186: 691–700, DOI: 10.1016/j.ajpath.2015.11.010.
17.
Allenbach Y, Uzunhan Y, Toquet S, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. Neurology 2020; 95: 70–78, DOI: 10.1212/WNL.0000000000009727.
18.
Hall JC, Casciola-Rosen L, Samedy LA, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: Expanding the clinical spectrum. Arthritis Care Res 2013; 65: 1307–1315, DOI: 10.1002/acr.21992.
19.
Cabezas-Rodríguez I, Morante-Bolado I, Brandy-García A, et al. Anti-MDA5 dermatomyositis mimicking psoriatic arthritis. Reumatol Clin 2018; 14: 224–226, DOI: 10.1016/j.reuma.2016. 10.010.
20.
Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study. J Am Acad Dermatol 2011; 65: 25–34, DOI: 10.1016/j.jaad.2010.09.016.
21.
Barailler H, Charles S, Goutorbe F, Devaux S. An unusual anti- melanoma differentiation-associated protein 5 amyopathic dermatomyositis. JAAD Case Rep 2019; 5: 383–385, DOI: 10.1016/j.jdcr.2019.02.019.
22.
Xu A, Lv X, Du F, Dai M. Cutaneous ulceration and digital gangrene in an anti-MDA5-positive overlap myositis. Rheumatol (Oxford) 2021; 60: 5880–5881, DOI: 10.1093/rheumatology/keab284.
23.
Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation- associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol 2018; 78: 776–785, DOI: 10.1016/j.jaad.2017.12.010.
24.
Chen Z, Cao M, Plana MN, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: A review of the literature and a meta-analysis. Arthritis Care Res 2013; 6: 1316–1324, DOI: 10.1002/acr.21985.
25.
Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of anti- melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatol (Oxford) 2012; 51: 1278–1284, DOI: 10.1093/rheumatology/ker518.
26.
Hozumi H, Fujisawa T, Nakashima R, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med 2016; 121: 91–99, DOI: 10.1016/j.rmed.2016.10.019.
27.
Yamaguchi K, Yamaguchi A, Itai M, et al. Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum. Clin Rheumatol 2019; 38: 3443–3450, DOI: 10.1007/s10067-019-04729-5.
28.
Zhou M, Ye Y, Yan N, et al. Noninvasive positive pressure ventilator deteriorates the outcome of pneumomediastinum in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis. Clin Rheumatol 2020; 39: 1919–1927. DOI: 10.1007/s10067-019-04918-2.
29.
Kawamoto S, Abe T, Nagahori K, et al. Anti-MDA5 Antibody-positive Dermatomyositis with Rapidly Progressive Interstitial Pneumonia Presenting with Nephrotic Syndrome during Treatment with Corticosteroids and Cyclosporine. Intern Med 2022; 61: 2007–2012, DOI: 10.2169/internalmedicine.8311-21.
30.
Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res 2014; 2014: 290797, DOI: 10.1155/2014/290797.
31.
Yang Q, Lyu K, Li J, et al. Anti-melanoma differentiation- associated 5 gene antibody-positive dermatomyositis exhibit three clinical phenotypes with different prognoses. Clin Exp Rheumatol 2022; 40: 304–308, DOI: 10.55563/CLINEXPRHEUMATOL/DF2OC3.
32.
Xu L, You H, Wang L, et al. Identification of Three Different Phenotypes in Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis Patients: Implications for Prediction of Rapidly Progressive Interstitial Lung Disease. Arthritis Rheumatol 2023; 75: 609–619, DOI: 10.1002/art.42308.
33.
Romero-Bueno F, Diaz del Campo P, Trallero-Araguás E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum 2020; 5: 776–790, DOI: 10.1016/j.semarthrit. 2020.03.007.
34.
Wu W, Guo L, Fu Y, et al. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis. Clin Rev Allergy Immunol 2021; 60: 293–304, DOI: 10.1007/s12016-020-08822-5.
35.
Tsuji H, Nakashima R, Hosono Y, et al. Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Pos. Arthritis Rheumatol 2020; 72: 488–498, DOI: 10.1002/art.41105.
36.
Fujisawa T, Hozumi H, Kamiya Y, et al. Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: A randomized, open-label trial. Respirology 2021; 26: 370–377, DOI: 10.1111/resp.13978.
37.
Chen Z, Wang X, Ye S. Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease. N Engl J Med 2019; 381: 291–293, DOI: 10.1056/nejmc1900045.
38.
Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation- associated 5 gene antibody-positive dermatomyositis. Rheumatol (Oxford) 2018; 57: 2114–2119, DOI: 10.1093/rheumatology/ key188.
39.
Takatani A, Koga T, Fujita Y, et al. Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis. Clin Immunol 2020; 215: 108451, DOI: 10.1016/j.clim.2020.108451.
40.
Ge Y, Li S, Tian X, et al. Anti-melanoma differentiation- associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clin Rheumatol 2021; 40: 2311–2317, DOI: 10.1007/s10067-020-05530-5.
41.
Wang LM, Yang QH, Zhang L, et al. Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-Associated gene 5-positive dermatomyositis. Rheumatol (Oxford) 2022; 61: 3704–3710, DOI: 10.1093/rheumatology/keab928.
42.
Jeter J, Wolf EG, Richards M, Hill E. Successful treatment of anti-MDA5 dermatomyositis associated cutaneous digital pulp ulcerations with hyperbaric oxygen therapy. J Clin Rheumatol 2020; 26: E266–E267, DOI: 10.1097/RHU.0000000000001114.
43.
Winayanuwattikun W, Vachiramon V. Botulinum Toxin Type A for the Treatment of Skin Ulcers: A Review Article. Toxins (Basel) 2022; 14, DOI: 10.3390/toxins14060406.
44.
Li T, Guo L, Chen Z, et al. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep 2016; 6, DOI: 10.1038/srep33226.
45.
Chen X, Jiang W, Jin Q, et al. Nintedanib could potentially lead to improvements in anti-melanoma differentiation- associated 5 dermatomyositis-associated interstitial lung disease. Clin Exp Rheumatol 2024; 42: 386–393, DOI: 10.55563/ clinexprheumatol/c0i032.
46.
Liang J, Cao H, Yang Y, et al. Efficacy and Tolerability of Nintedanib in Idiopathic-Inflammatory-Myopathy-Related Interstitial Lung Disease: A Pilot Study. Front Med 2021; 8: 626953, DOI: 10.3389/fmed.2021.626953.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Udostępnij
ARTYKUŁ POWIĄZANY
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
Przetwarzamy dane osobowe zbierane podczas odwiedzania serwisu. Realizacja funkcji pozyskiwania informacji o użytkownikach i ich zachowaniu odbywa się poprzez dobrowolnie wprowadzone w formularzach informacje oraz zapisywanie w urządzeniach końcowych plików cookies (tzw. ciasteczka). Dane, w tym pliki cookies, wykorzystywane są w celu realizacji usług, zapewnienia wygodnego korzystania ze strony oraz w celu monitorowania ruchu zgodnie z Polityką prywatności. Dane są także zbierane i przetwarzane przez narzędzie Google Analytics (więcej).
Możesz zmienić ustawienia cookies w swojej przeglądarce. Ograniczenie stosowania plików cookies w konfiguracji przeglądarki może wpłynąć na niektóre funkcjonalności dostępne na stronie.
Możesz zmienić ustawienia cookies w swojej przeglądarce. Ograniczenie stosowania plików cookies w konfiguracji przeglądarki może wpłynąć na niektóre funkcjonalności dostępne na stronie.
